Physician profile
Hector Picon
NPI 1457416869
$7,945.86
in general payments reported to CMS, 2019-2025
33 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $1,131 · 2021: $987 · 2022: $1,765 · 2023: $1,657 · 2024: $877 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,642.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,074.37 | 2019-2024 | Xarelto |
| Abbott Laboratories | $660.51 | 2019-2025 | Aveir, Assurity |
| Shockwave Medical, INC | $426.84 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Novartis Pharmaceuticals Corporation | $366.02 | 2019-2024 | |
| Abiomed | $362.28 | 2019-2023 | Impella |
| Medtronic, INC. | $352.99 | 2021-2024 | Symplicity G3, Onyx Frontier |
| Astrazeneca Pharmaceuticals LP | $333.69 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $276.90 | 2019-2024 | Eliquis |
| Cardiovascular Systems INC. | $246.96 | 2020-2022 | |
| Medtronic Vascular, INC. | $240.04 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $204.27 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $189.01 | 2019-2023 | Watchman Access System |
| Atricure, INC. | $184.63 | 2023 | |
| Amgen INC. | $153.53 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $151.90 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $140.10 | 2019-2020 | |
| Chiesi USA, INC. | $98.86 | 2019-2023 | Cleviprex, Kengreal |
| Cvrx, INC. | $75.74 | 2022 | |
| W. L. Gore & Associates, INC. | $54.92 | 2019-2021 | |
| Osprey Medical INC | $53.61 | 2019-2020 | |
| Nuwellis, INC. | $36.72 | 2019-2022 | |
| Cmp Pharma, INC. | $35.93 | 2021 | |
| Lantheus Medical Imaging, INC. | $33.06 | 2022-2023 | Definity |
| Esperion Therapeutics, INC. | $29.26 | 2022-2024 | Nexletol |
| Impulse Dynamics (USA) INC. | $25.39 | 2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $22.58 | 2021 | |
| Daiichi Sankyo INC. | $21.45 | 2023 | Injectafer |
| Terumo Medical Corporation | $19.64 | 2019 | |
| Novo Nordisk INC | $19.03 | 2024 | Rybelsus, Ozempic |
| Biotronik INC. | $16.53 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $15.24 | 2024 | |
| Penumbra, INC. | $13.86 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Picon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.